Author: Michael Haydock
Publisher: Datamonitor Healthcare
MEDI-7510 (AstraZeneca) is a Phase II intramuscular vaccine consisting of soluble respiratory
syncytial virus (RSV) fusion (F) protein with a glucopyranosyl lipid adjuvant (GLA). MEDI-7510 is being
targeted at the elderly population, which is in contrast to the company’s portfolio of live-attenuated
vaccines for which it is pursuing approval for use in infants. The 2015 success of Novavax’s rival RSV F
vaccine in a Phase II proof-of-efficacy study partially de-risks MEDI-7510’s development program, as
both vaccines have similar designs and aim to elicit palivizumab-competing antibody (PCA) responses
against the RSV F protein. However, the promising efficacy data also raise the bar for MEDI-7510, and
provide a standard against which MEDI-7510 must improve if it aims to capture significant market
share from its more advanced rival. Datamonitor Healthcare believes that MEDI-7510’s inclusion of
GLA could allow it stimulate superior T-helper type 1 (TH1) cellular immunity compared to Novavax’s
vaccine, but it is unclear whether the stimulation of a broader immune response will translate into
significantly improved protection.
MEDI-7510 is a Phase II intramuscular vaccine comprising RSV F protein with a GLA. The vaccine is
being developed for the prevention of severe disease caused by RSV in adults aged over 60 years.
AstraZeneca has formed an exclusive agreement with Immune Design to use the latter’s GLA – a
synthetic molecule licensed from Immune Design’s GLAAS discovery platform – in vaccines for RSV
and two other undisclosed indications (Immune Design, 2014).
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 MEDI-7510 : Respiratory syncytial virus vaccines
LIST OF FIGURES
9 Figure 1: MEDI-7510 for respiratory syncytial virus – SWOT analysis
LIST OF TABLES
4 Table 1: MEDI-7510 drug profile
5 Table 2: Summary of the ongoing Phase II trial of MEDI-7510 for respiratory syncytial virus
7 Table 3: Summary of completed Phase I trials of MEDI-7510 for respiratory syncytial virus
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.